Candel Therapeutics Q2 FY26 net loss widens to $38.9 million; R&D expense more than doubles to $19.8 million - CADL News | RalliesCandel Therapeutics Q2 FY26 net loss widens to $38.9 million; R&D expense more than doubles to $19.8 million
C
CADL• Q2 loss widens as spending rises
- Candel Therapeutics posted a Q2 2026 net loss of $38.9 million, widening from a loss of $4.8 million.
- R&D expense rose to $19.8 million from $7 million, driven by higher clinical-trial and manufacturing costs.
- G&A expense increased to $6.9 million from $4.2 million on higher commercial-readiness and employee-related costs.
Cash position and pipeline update
- Cash and cash equivalents climbed to $201.6 million at June 30, 2026, with runway expected into Q1 2028.
- The company targets a prostate-cancer BLA for aglatimagene in Q4 2026, with a potential U.S. launch in 2027 if approved.
•
